European Commission Grants Approval of OGSIVEO® ( nirogacestat ) for the Treatment of Adults with Desmoid Tumors

Benzinga
2025.08.18 14:03
portai
I'm PortAI, I can summarize articles.

STAMFORD, Conn., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission ( EC ) granted marketing authorization for OGSIVEO® ( nirogacestat ) , an oral gamma secretase inhibitor, as ...

Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer